Summary

The 7 major ischemic stroke markets reached a value of US$ 3.0 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 5.2 Billion by 2034, exhibiting a growth rate (CAGR) of 5.24% during 2024-2034.

The ischemic stroke market has been comprehensively analyzed in IMARC's new report titled "Ischemic Stroke Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". An ischemic stroke occurs when a blockage or clot in an artery in the brain prevents blood flow to a specific brain area. The lack of blood flow deprives brain cells of oxygen and nutrients, leading to damage and often permanent disability. Ischemic strokes are categorized into two types: thrombotic strokes, caused by a blood clot that forms in an artery in the brain, and embolic strokes, which occur due to a clot that forms in another part of the body and spreads to the brain. The common symptoms associated with the ailment include trouble speaking and understanding speech, paralysis or numbness of the arm, face, or leg, blurred or blackened vision, dizziness, severe headaches, altered consciousness, difficulty walking, etc. Additionally, individuals suffering from this disease may experience neck stiffness, emotional instability, personality changes, confusion or agitation, nausea, vomiting, memory loss, etc. The diagnosis of ischemic stroke is made by a combination of neurological examination, imaging studies, and other tests. The healthcare provider may perform several diagnostic procedures, including computerized tomography (CT) scan, electrocardiogram (ECG), magnetic resonance imaging (MRI), electroencephalogram (EEG), etc., to confirm a diagnosis.

The rising cases of high cholesterol that cause fatty deposits to form in the arteries and increase the likelihood of blood clots are primarily driving the ischemic stroke market. In addition to this, the elevating incidences of several associated risk factors, such as obesity, smoking, excessive alcohol consumption, high blood pressure, etc., are further augmenting the market growth. Moreover, the emerging popularity of tissue plasminogen activator, which breaks up the clot and stabilizes blood circulation to the brain, for treating the ailment is also creating a positive outlook for the market. Apart from this, the inflating application of cerebral angiography that uses contrast dye to visualize a clear X-ray of the blockages or abnormalities in the brain blood vessels for diagnosing the condition is further bolstering the market growth. Additionally, several key players are making extensive investments in R&D activities to improve understanding of disease pathology and develop advanced tools for disease detection and diagnosis with quicker and more accurate results. This, in turn, is acting as a significant growth-inducing factor. Furthermore, the widespread adoption of anticoagulant drugs, such as heparin and warfarin, which can prevent blood clots from forming and lower the risk of recurrent stroke, is expected to drive the ischemic stroke market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the ischemic stroke market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for ischemic stroke and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the ischemic stroke market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the ischemic stroke market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the ischemic stroke market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current ischemic stroke marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the ischemic stroke market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the ischemic stroke market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the ischemic stroke market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of ischemic stroke across the seven major markets?
What is the number of prevalent cases (2018-2034) of ischemic stroke by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of ischemic stroke by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with ischemic stroke across the seven major markets?
What is the size of the ischemic stroke patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of ischemic stroke?
What will be the growth rate of patients across the seven major markets?

Ischemic Stroke: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for ischemic stroke drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the ischemic stroke market?
What are the key regulatory events related to the ischemic stroke market?
What is the structure of clinical trial landscape by status related to the ischemic stroke market?
What is the structure of clinical trial landscape by phase related to the ischemic stroke market?
What is the structure of clinical trial landscape by route of administration related to the ischemic stroke market?

ページTOPに戻る

Table of Contents

1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Ischemic Stroke - Introduction
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence

5 Ischemic Stroke - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment

6 Patient Journey

7 Ischemic Stroke - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)

7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)

8 Ischemic Stroke - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm

9 Ischemic Stroke - Unmet Needs

10 Ischemic Stroke - Key Endpoints of Treatment

11 Ischemic Stroke - Marketed Products
11.1 List of Ischemic Stroke Marketed Drugs Across the Top 7 Markets
11.1.1 Aggrenox (Aspirin/dipyridamole extended release) - Boehringer Ingelheim
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Activase (Alteplase) - Boehringer Ingelheim
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Brilinta (Ticagrelor) - AstraZeneca
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 Ischemic Stroke - Pipeline Drugs
12.1 List of Ischemic Stroke Pipeline Drugs Across the Top 7 Markets
12.1.1 MultiStem - Athersys
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Elezanumab - AbbVie
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 RNS60 - Revalesio Corporation
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 SB623 - SanBio
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 ACT017 - Acticor Biotech
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. Ischemic Stroke - Attribute Analysis of Key Marketed and Pipeline Drugs

14. Ischemic Stroke – Clinical Trial Landscape
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events

15 Ischemic Stroke - Market Scenario
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Ischemic Stroke - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Ischemic Stroke - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Ischemic Stroke - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Ischemic Stroke - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Ischemic Stroke - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Ischemic Stroke - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Ischemic Stroke - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Ischemic Stroke - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Ischemic Stroke - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Ischemic Stroke - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Ischemic Stroke - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Ischemic Stroke - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Ischemic Stroke - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Ischemic Stroke - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Ischemic Stroke - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Ischemic Stroke - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Ischemic Stroke - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Ischemic Stroke - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Ischemic Stroke - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Ischemic Stroke - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Ischemic Stroke - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Ischemic Stroke - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Ischemic Stroke - Access and Reimbursement Overview

16 Ischemic Stroke - Recent Events and Inputs From Key Opinion Leaders

17 Ischemic Stroke Market - SWOT Analysis
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats

18 Ischemic Stroke Market – Strategic Recommendations

19 Appendix